Prosecution Insights
Last updated: November 04, 2026
Application No. 18/725,616

COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING PRESBYOPIA

Non-Final OA §103§112
Filed
Jun 28, 2024
Priority
Dec 28, 2021 — CN 202111622501.X +1 more
Examiner
JOHNSON, CHRISTOPHER LINDSAY
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shenyang Xingqi Pharmaceutical Co. Ltd.
OA Round
1 (Non-Final)
47%
Grant Probability
Moderate
1-2
OA Rounds
1y 0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allowance Rate
17 granted / 36 resolved
-12.8% vs TC avg
Strong +79% interview lift
Without
With
+79.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
49 currently pending
Career history
87
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
38.2%
-1.8% vs TC avg
§102
19.6%
-20.4% vs TC avg
§112
30.2%
-9.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 36 resolved cases

Office Action

§103 §112
DETAILED ACTION This office action is in response to the Applicant’s filing dated July 31st, 2026. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application is a 371 of PCT/CN2022/142375 filed on December 27th, 2022; and claims benefit of foreign priority of CN202111622501.X filed on December 28th, 2021. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Status of Claims Claims 1-20 are pending in the instant application. Acknowledgement is made of Applicant’s remarks July 31st, 2026. Election/Restrictions Applicant’s election without traverse of Group I in the reply filed on July 31st, 2026 is acknowledged. Claims 10 and 18-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on July 31st, 2026. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 16 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 16 contains the trademark/trade name “Span”. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe sorbitan monooleate and, accordingly, the identification/description is indefinite. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-9 and 11-17 are rejected under 35 U.S.C. 103 as being unpatentable over Pinelli (WO 2017/115238 A1); in view of Abad (WO2013/041967 A2). Regarding claims 1-9 and 11-17, Pinelli teaches a composition useful for treating presbyopia (page 4, lines 20-22) comprising <0.40% pilocarpine, which can be present as a pharmaceutically acceptable salt (e.g. pilocarpine nitrate) (page 7, lines 17-27); <0.090% an alpha-stimulant agonist, namely naphazoline and pharmaceutically acceptable salts thereof (e.g. naphazoline hydrochloride) (page 7, lines 17-23 and 28-30; page 8, line 1); and <0.090% a non-steroid anti-inflammatory agent (NSAID), namely ketorolac (page 7, lines 17-23; page 8, lines 2-7). Pinelli teaches that the pH value of the composition ranges between 4.5-8.5 (page 12, lines 10-11). Pinelli teaches that the composition may further comprise boric acid (page 15, Example 1, lines 3-5); citric acid (page 6, lines 26-30; page 10, lines 20-28); polysorbate 80 (page 10, lines 20-28); EDTA (page 10, lines 20-28; page 16, lines 25-26) and polyoxyethylene (page 10, lines 24-25; page 11, lines 10-11). Pinelli does not explicitly teach a composition with 0.5-1.5% muscarinic acetylcholine receptor M3 agonist, 0.005-0.5% naphazoline and 0.1-1% ketorolac, or the specific weights of the claimed excipients. Abad teaches a composition useful for treating presbyopia (page 3, lines 24-30; page 7, lines 26-29) comprising 0.01-4% pilocarpine (page 3, lines 30-32; page 9, lines 4-6; page 33, claim 6); 0.01-0.5% an alpha-stimulant agonist, namely naphazoline (page 3, lines 32-34; page 9, lines 6-7; page 33, claim 10); and 0.01-2% a non-steroid anti-inflammatory agent (NSAID) (page 3, lines 27-30; page 9, lines 7-8). Abad teaches that the composition may further comprise boric acid (page 17, lines 8-10); citric acid (page 17, lines 8-10); sodium citrate buffer (page 17, line 12); polysorbate 80 (page 18, line 1); and EDTA (page 17, line 18). It would have been prima facie obvious to one of ordinary skill in the art to utilize the amount of pilocarpine, naphazoline and ketorolac taught by Pinelli, in view of the teachings of Abad, as a starting point for optimizing the amount of pilocarpine, naphazoline and ketorolac utilized to treat presbyopia since both Pinelli and Abad, in their respective composition teachings, teaches the combination of muscarinic acetylcholine receptor M3 agonist, namely pilocarpine, naphazoline and an NSAID, namely ketorolac is useful for treating presbyopia and because dosage and treatment regimen are result-effective variables, i.e. a variable that achieves a recognized result. Therefore, the determination of the optimum or workable dosages would have been well within the practice of routine experimentation by the skilled artisan. Furthermore, absent any evidence demonstrating a patentable difference between the compositions and the criticality of the claimed dosage range, the determination of the optimum or workable dosing regimen given the guidance of the prior art would have been generally prima facie obvious to the skilled artisan. Please see MPEP 2144.05 [R-2](II)(A) and In re Aller, 220 F. 2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). ("[W]here the general conditions of claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation."). Taken together, all of this would result in the composition of instant claims 1-9 and 11-17 with a reasonable expectation of success. Conclusion Claims 1-9 and 11-17 are rejected. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER L JOHNSON whose telephone number is (571)272-1672. The examiner can normally be reached Monday - Friday 08:00AM - 5:00PM EST with Flex on Fridays. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.L.J./Examiner, Art Unit 1691 /RENEE CLAYTOR/Supervisory Patent Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Jun 28, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780818
EPOXYAMIDES AS KRAS G12C AND KRAS G12D INHIBITORS AND METHODS OF USING THE SAME
4y 6m to grant Granted Nov 03, 2026
Patent 12780812
PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF
3y 2m to grant Granted Nov 03, 2026
Patent 12760025
SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS AND METHODS OF THERAPEUTIC USE THEREOF
3y 2m to grant Granted Oct 13, 2026
Patent 12746289
ANTITUMOR PHARMACEUTICAL COMPOSITION AND USE THEREOF
3y 4m to grant Granted Sep 29, 2026
Patent 12741979
Process for preparing a phosphoramidite and further reaction thereof to the monophosphite
2y 9m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
47%
Grant Probability
99%
With Interview (+79.2%)
3y 4m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 36 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month